Plasmalogens and Alzheimer’s disease: a review
Xiao Q. Su 1*, Junming Wang 2 and Andrew J. Sinclair 3,4

Abstract
Growing evidence suggests that ethanolamine plasmalogens (PlsEtns), a subtype of phospholipids, have a close association with Alzheimer’s disease (AD). Decreased levels of PlsEtns have been commonly found in AD patients, and were correlated with cognition deficit and severity of disease. Limited studies showed positive therapeutic outcomes with plasmalogens interventions in AD subjects and in rodents. The potential mechanisms underlying the beneficial effects of PlsEtns on AD may be related to the reduction of γ-secretase activity, an enzyme that catalyzes the synthesis of β-amyloid (Aβ), a hallmark of AD. Emerging in vitro evidence also showed that PlsEtns prevented neuronal cell death by enhancing phosphorylation of AKT and ERK signaling through the activation of orphan G-protein coupled receptor (GPCR) proteins. In addition, PlsEtns have been found to suppress the death of primary mouse hippocampal neuronal cells through the inhibition of caspase-9 and caspase-3 cleavages. Further in-depth investigations are required to determine the signature molecular species of PlsEtns associated with AD, hence their potential role as biomarkers. Clinical intervention with plasmalogens is still in its infancy but may have the potential to be explored for a novel therapeutic approach to correct AD pathology and neural function.

Keywords: Plasmalogens, Alzheimer’s disease, Biomarker, Therapeutic efficacy, Mechanisms of action

Introduction
Plasmalogens are a subclass of phospholipids, mainly found in the cell membranes. Ethanolamine plasmalogens (PlsEtns) are the predominant phospholipids in the brain, kidney, lungs and skeletal muscle [1]. They are characterised by having a vinyl ether bond linking the fatty aldehyde to the glycerol molecule in the 1-position and a fatty acyl bond in the 2-position. There has been an increasing interest in plasmalogens in the last two decades due to their biological roles in the body and association with various diseases. It has been reported that reduced levels of PlsEtns in the plasma are associated with Alzheimer’s disease (AD), cardiovascular disease, hypertension, cancer and respiratory disease [1–7]. Several mechanisms associated with the action of PlsEtns have been suggested by various authors, through predominantly in vitro studies. These include helping maintaining membrane physical bilayer properties to facilitating membrane fusion and signal transduction processes, including cholesterol efflux [8, 9]; preventing oxidative stress; and reducing inflammatory response [7, 10–13].

This review focuses on the association(s) between plasmalogens and Alzheimer’s disease. AD is a complex neurodegenerative disease characterized by progressive memory loss and cognitive impairment associated with progressive neural cell loss predominantly observed in the hippocampus [14, 15]. The causes and mechanisms of the development of AD are not fully elucidated, although progressive accumulation of β-amyloid fibrils (Aβ plaques) and abnormal forms of tau (tau tangles) within and outside of neurons are considered to be the neuropathological hallmark [14, 15]. Currently, there is no established biomarker for AD to allow early detection of the risks for the disease and potential intervention to prevent disease progression [16]. Although available anti-dementia agents have shown some impacts on AD in a limited period of time, more desirable therapeutic agents with potent efficacy and long-lasting effects are needed.

The aim of this review is to provide an overview of current knowledge of the biology of PlsEtns with an emphasis on their association with AD. We briefly discuss the chemical and biological properties of PlsEtns; and

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
present the most recent literature evidence on their association with AD, their mechanisms of action and potential use as a diagnostic and prognostic biomarker and new therapeutic targets for AD.

Properties of Plasmalogens

Plasmalogens are subclass of phospholipids characterized by the presence of a vinyl ether bond at the sn-1 position and an ester bond at the sn-2 position of a glycerol backbone. The sn-1 position consists of C16:0 (palmitic acid), C18:0 (stearic acid) or C18:1 (oleic acid) carbon chains, and the head group is usually either ethanolamine or choline, thus there are two predominant types of plasmalogens, ethanolamine plasmalogens (PlsEtns) and choline plasmalogens (PlsChos). The sn-2 position is predominately occupied by a polyunsaturated fatty acid, specifically arachidonic acid (ARA) or docosahexaenoic acid (DHA) [1–3, 17] (Fig. 1). Plasmalogens are found in almost all mammalian tissues, although the highest concentrations are found in brain, red blood cells, skeletal muscle and spermatozoa and can represent as much as 18–20% of the total phospholipids in cell membranes [1, 15]. Their distribution and content varies significantly in different tissue/cell types, with PlsEtns 10-fold higher than PlsChos except in muscle [18]. Brain has the highest content of PlsEtns and it constitutes 30 mol% of total phospholipids in human brain, whereas heart muscle has a higher content of PlsChos [3, 7, 17]. Moderate amounts of plasmalogens are found in kidney, skeletal muscle, spleen and blood cells, while liver shows low plasmalogen content [2]. The unique functions of plasmalogen species in the body are directly related to the property of the sn-1 vinyl ether bond and the enrichment of polyunsaturated fatty acids at the sn-2 position [1].

Phospholipids are either provided directly from the diet or via de novo synthesis. Dietary phospholipids are typically consumed in low amounts, about 2–5 g per day, through the intake of almost all foods, especially eggs, soybean, meat, fish, milk and other dairy products [19, 20]. Dietary plasmalogens are absorbed in the intestine and delivered to tissues [21] although the details of digestion, absorption and subsequent transport of dietary plasmalogens are essentially unknown. A similar situation prevails for absorption and subsequent transport of dietary diacyl phospholipids where specific details are still far from clear [22, 23]. Circulating plasmalogens are either derived from dietary sources and/or are synthesized mainly in the liver and gastrointestinal epithelium [24, 25] and are exported into the blood via transport proteins of which low density lipoprotein (LDL) is a major carrier [26]. From there they are transported to the brain via a LDL receptor-mediated transcytosis pathway [27]. Plasmalogens are not only important structural phospholipids in the cell membranes, they are also reservoirs of secondary messages and mediators of membrane dynamics and involved in membrane fusion, ion transport, cholesterol efflux, membrane-bound enzyme activity, and diffusion of signal-transduction molecules. The biological functions of plasmalogens have been well documented in the literature [1, 2, 7–9, 28–30]. Plasmalogens are also antioxidants, and have been shown to have a protective role against oxidative stress, especially in the brain and heart [12]. The biosynthesis of plasmalogens is initiated in peroxisomes and terminated in the endoplasmic reticulum (Fig. 2) [7, 31]. Defects occurring at the synthetic process may affect their biological functions in the body. Inherited (primary) plasmalogen deficiency is rare (1/100,000) and has been found to be associated with peroxisomal disorders resulting from mutations /defects in the genes involved in the synthesis of peroxisomal protein transporter or enzymes required for plasmalogen syntheses [1]. Primary plasmalogen deficiency associated with the inherited human peroxisomal disorder, rhizomelic chondrodysplasia punctata (RCDP) shows deficiency of tissue plasmalogens and results in severe disorders in multiple organs such as brain, bone, lens, kidney and heart [17]. Secondary deficiency of plasmalogens resulting from decreased synthesis and/or increased degradation of plasmalogens, was reported to be associated with metabolic and inflammatory disorders such as cardiac diseases, diabetes mellitus, cancer, respiratory disease and
Alzheimer’s disease [1–3, 7, 17]. Choline plasmalogens play an important role in cardiac tissue, but represent a minor species in most other organs thus most likely an insignificant role in those organs.

Alzheimer’s disease
AD is a complex neurodegenerative disease characterized by progressive memory loss and cognitive impairment [14]. It is the most common cause of dementia in older people. It is associated with progressive neural cell loss predominantly observed in the hippocampus. The cause and mechanism of AD has not been fully elucidated, although progressive accumulation of β-amyloid fibrils (Aβ plaques) and abnormal forms of tau (tau tangles) within and outside of neurons are considered to be the neuropathological hallmarks [14, 15, 32–34]. A number of other neuropathologies of AD have also been suggested including neuronal shrinkage, hypomyelination, neuroinflammation, mitochondrial oxidative stress, endoplasmic reticulum stress, and cholinergic dysfunction [1, 3, 35–37]. Various risk factors promote pathological changes well before the onset of clinical symptoms of AD and this includes age; cardiovascular risk; lifestyle related factors such as obesity, diabetes, depression, smoking, and insufficient diet; family history and possibly genetic factors; environmental factors (aluminum and or zinc accumulation in the brain), serious head injury [1, 14]. It is estimated that the prevalence of AD may reach to 74 million worldwide by 2030 [38], therefore early diagnosis and effective treatment are crucial in order to reduce the incidence of the disease. However, as the pathology of AD begins well before symptoms are manifested, the progressive neurodegeneration and neural cell loss in the brain are often neglected until impairments in cognitive performance become noticeable [14]. When the loss of neuronal cells reaches a critical point with cognition deficit, approximately 50 to 80% of cells have already died, a condition that the course of the disease progression becomes difficult or impossible to be changed. Currently, there are no established biomarkers for AD to allow early detection of the risks for the disease and potential intervention to prevent disease progression [16]. Among several factors being studied as possible biomarkers for AD are the amyloid-β in the brain as shown in positron emission tomography (PET) imaging and levels of certain proteins in fluid (for example, levels of Aβ and phosphorylated tau, a major microtubule associated protein of a mature neuron) in the cerebrospinal fluid and levels of particular groups of proteins in blood) [14]. However, those tests are either invasive or costly. The sensitivity of those tests also reflect imperfection for clinical diagnosis [39]. There is also no effective treatment for AD although some anti-dementia agents such as cholinesterase inhibitors and Memantine (Namenda) have shown some improvements in cognition, global function and/or activities of daily living in some patients with AD for a limited period of time [40, 41].
Association of PlsEtns with Alzheimer's disease and their potential use as a biomarker

There are increasing numbers of studies in the last two decades which have reported a direct link of plasmalogens deficiency and AD. Since the first study showing a significant deficiency of PlsEtns relative to PE in the post-mortem brain samples of AD patients was published in 1995 [42], much attention has been devoted to PlsEtns and their association with AD. Recent studies have predominately focused on the potential therapeutic role of PlsEtns and the molecular mechanisms underlying their beneficial effects. Table 1 summarises key studies focusing on the relation of PlsEtns and AD, in particular those published in the last 5 years.

It has been demonstrated that decreased levels of PlsEtns have not only found in the post-mortem brain samples [43–46], but also in cerebrospinal fluid [43, 47], plasma, serum and red blood cells of AD patients [30, 48–50]. A 70% reduction of PlsEtns has been observed in the brain of AD patients compared with healthy brain tissues [30, 32]. The deficiency of PlsEtns in neurodegeneration was found to be specific to AD and not observed at the primary site of neurodegeneration in Huntington's disease nor Parkinson's diseases [3, 44]. It was also reported that more remarkable decrease of PlsEtns was observed in the neurodegeneration sites such as hippocampus, temporal cortex and frontal cortex, but not the cerebellum of AD brain [15, 42, 44]. Gray matter PlsEtns was found to have different fatty acid composition from white matter PlsEtns at sn-2 position. In white matter, the sn-2 position is dominated by oleic acid while in gray matter docosahexaenoic acid (DHA, 22:6) and arachidonic acid (20:4) predominate [3]. Furthermore, reduction of PlsEtns in different brain tissues has been reported to be associated with different stage of AD progression. White matter PlsEtns deficiency was found to be associated with early stage of disease, and a dramatic decrease of up to 40 mol% of the total PlsEtns has been observed in the post-mortem AD brain [44, 51]. This decrease of PlsEtns was not correlated with cognition functions [3]. While gray matter PlsEtns deficiency has shown a correlation with the severity of disease, with ~ 10 mol% - 30 mol% of the total PlsEtns reduction being recorded in the post-mortem AD brain corresponding to very mild and severe disease status [3, 44]. Consistently, a ≤ 75% decrease of serum plasmalogens levels in AD patients compared with age-matched controls has also shown an association with a cognitive function decline [30]. There have been many reports showing that DHA is related closely to brain functions [52–56]. Therefore, the association of gray matter PlsEtns and white matter PlsEtns with different stage of AD may be attributed at least in part to the discrepancy in their fatty acid compositions at sn-2 position, and/or their major functions in neuronal cells compared with myelin. Correspondingly, observations have shown that levels of DHA and DHA-containing PlsEtns were significantly reduced in the brain, liver, plasma and serum of AD patients and the extent of decrease was correlated with cognitive deficit in AD patients [3, 24, 30, 49]. Furthermore, the severity of disease was improved when circulating levels of DHA and plasmalogens were high, particularly PlsEtns containing DHA at sn-2 [30, 49].

The cause of PlsEtns deficiency in AD brain is not clear. It is also not known whether the decrease of PlsEtns in the patients with AD is the cause or the consequence of the disease. It may be both [15], although an earlier suggestion indicated that it may be the cause of the ethology of AD [57]. A few possible mechanisms with regards to the decrease of PlsEtns in AD have been suggested including peroxisome dysfunction, oxidative stress, alterations in membrane lipid rafts and inflammatory responses [2, 3, 42, 58, 59]. Plasmalogens synthesis is initiated in peroxisomes [31], and therefore changes/damages in peroxisome would result in alterations in plasmalogen synthesis. Peroxisome deficits have been reported in the liver and brain of AD subjects [24, 58, 60]. A correlation was also observed between increased long chain fatty acids (VLCFAs: behenic acid C22:0, lignoceric acid C24:0 and hexacosanoic acid C26:0), decreased plasmalogens in AD brain, and increased peroxisome volume density in neuronal cells [58]. All of these VLCFAs are metabolized in peroxisomes, thus these data again support peroxisome dysfunction in AD [3]. Furthermore, changes in VLCFAs and PUFA-containing plasmalogens also show impacts on functional performance. An increase of VLCFAs in the cortex, and decrease in DHA-containing plasmalogens in brain, liver and plasma was found to be associated with cognitive deficit in AD patients [24, 30, 44, 58].

Loss of PlsEtns in the AD brain could also be related to oxidative stress, leading to plasmalogen degradation by reactive oxygen species (ROS) [1]. The presence of a vinyl–ether bond makes plasmalogens more susceptible to oxidative stress [61]. This suggests that plasmalogens may act as scavengers to protect other lipids and lipoproteins from oxidative damages [11, 62]. The antioxidant effect of plasmalogens has been reported towards a wide range of ROS [10, 59]. Reduced plasmalogens might further enhance ongoing oxidative damage in AD, and alter membrane properties to promote further damage [1]. The lipid environment in the cell membrane could affect amyloid precursor protein processing through processing enzymes as they are integral membrane proteins and the Aβ cleavage takes place within the membrane. In addition, increased membrane free cholesterol associated with PlsEtns deficiency increased
Table 1  Plasmalogen (Pls) deficiency and their therapeutic use in AD and related disorders, and emerging molecular evidence on their neuronal protection role

| Author          | Design                                      | Objectives                                                                 | Outcomes                                                                                     |
|-----------------|---------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Fujino et al.   | Human studies                               | To test the efficacy of oral administration of Pls on cognitive function and blood Pls changes in patients with mild AD and MCI. Primary outcome: Mini Mental State Examination-Japanese (MMSE-J); secondary outcomes: Wechsler Memory Scale-Revised (WMS-R), Geriatric Depression Scale-Short Version-Japanese (GDS-S-J), and concentration of PlsEtns in circulation. | Oral administration of Pls significantly improved memory among female mild AD patients and those aged below 77 years as shown in WMS-R test. Mild AD patients showed a significantly greater decrease in plasma PlsEtns in the placebo group than in the treatment group. |
| Wood et al.     | Serum samples of clinical diagnosed Late-Onset AD (LOAD) patients (n = 90), patients with mild cognitive impairment (MCI), n = 77, and controls (n = 51) aged 76–78 were analyzed by lipodomics. | To investigate the levels of PlsEtns and diacylglycerols utilizing high resolution mass spectrometry, and correlate the lipid levels with disease. | Three patient cohorts within each clinical diagnosis (LOAD and MCI) were observed: lower circulating PlsEtns; higher circulating diacylglycerols; and neither of these two lipid alterations. More patients showed low level of PlsEtns in advanced stage of disease. |
| Yamasita et al. | Plasma and red blood samples of 28 AD patients (age: 72.5 ± 1.3) and 28 normal control subjects (age: 74.1 ± 1.3) were analyzed. Evaluation of plasma Aβ was correlated with phosphatidylcholine hydroperoxide (PCOOH), and PlsEtns in the blood of patients with AD. | To investigate the interaction of Aβ, peroxidation of phosphatidylcholine and PlsEtns in AD patients. | Plasma from patients with AD showed lower concentrations of PlsEtn species, especially DHA-containing PlsEtn. In addition, lower PlsEtn and higher PCOOH levels were observed in red blood cells (RBC) of AD patients. In both AD and control blood samples, PCOOH levels of RBC tended to correlate with plasma levels of Aβ40. |
| Wood et al.     | Lipidomics analysis of post-mortem cerebrospinal fluid (CSF), frontal cortex grey matter, and sub- jacent white matter | To define potential biomarkers that distinguishes cognitively intact subjects from those with incipient or established dementia; and understands the role of brain lipids in pathophysiology of aging and age-related cognitive impairment. | Monoacylglycerols (IMG), diacylglycerols (DAG), and fatty acid 26:0 were elevated in the grey matter of the mild cognitive impairment (MCI) and old dementia (OD) cohorts. PlsEtns were decreased in the grey matter of the young dementia (YD) and OD cohorts while and phosphatidylethanolamines were lower in the MCI, YD and OD cohorts. |
| Wood et al.     | The serum PlsEtns of 40 AD patients and 66 controls aged 67–89 years were analyzed and correlated with cognitive functions using AD assessment scale-cognitive (ADAS-Cog). Serum PlsEtns of AD patients were retested 1 year later. | To evaluate the relation between the level of circulating PlsEtns and cognitive function using ADAS-Cog in AD patients in comparison with controls. | Only subjects with serum DHA-PlsEtn ≤75% or less of normal levels exhibited cognitive decline over a 12 month period. There was no change in ADAS-Cog scores among participants with normal serum PlsEtn levels at baseline (> 75%). |
| Goodnow et al.  | The serum samples of 324 dementia subjects (3 groups: low, moderate and severe cognitive impairments) were analyzed and compared with 68 cognitive normal subjects aged 50–90 years to investigate the relations between dementia severity and PlsEtn levels. 209 healthy subjects aged 50–95 years were divided into 3 age groups (50–59, 60–69, and 70–95 years) and their serum were analyzed to determine the effect of age on PlsEtns levels. Postmortem serum samples of subjects with AD (n = 20) and those without AD pathology (n = 19) were analyzed to compare the serum PlsEtns levels. Serum from 50 clinically diagnosed AD subjects (3 stages), who were later confirmed to have AD upon postmortem examination were analyzed to determine the DHA PlsEtns levels. Serum samples of 80 Japanese AD subjects and 80 non-demented Japanese subjects living in Japan were analyzed to determine the effect of ethnic or environmental differences on serum DHA PlsEtns levels in AD. | To determine PlsEtns depletion in the brain of subjects with AD, and whether decreased brain levels of PlsEtns in AD are a centrally mediated effect caused by Aβ accumulation or there are much broader changes occurred. | The levels of PlsEtns species were significantly reduced in all three groups of AD subjects, and the decrease was correlated with the severity of AD. Peroxisome-derived PlsEtns was also significantly reduced in all stages of AD. Subject % with very low PlsEtns in the 60–69 year cohort was more than double than other two groups. ↑ mortality rate in both AD subjects and peroxisomal disorders with ↓ PlsEtns. Serum PlsEtns levels were significantly reduced in the postmortem (55%) AD subjects, and clinically diagnosed AD subject (47%). The decrease was related to the severity of disease. Serum DHA-PlsEtns levels were significantly reduced in the AD subjects. |
| Han et al.      | Post-mortem human brain tissue and mouse brain tissues from two animal models of AD, APPV717F and APPSw were analyzed using Electrospray ionization mass spectrometry (ESI-MS) | To examine systematically plasminogen content in cellular membranes of gray and white matter from different regions of human subjects with a spectrum of AD clinical dementia ratings. | A dramatic decrease in PlsEtns content (up to 40 mol% of total PlsEtns) in white matter at a very early stage of AD; a correlation of the deficiency in gray matter PlsEtns content (10 mol% - 30 mol% deficiency) with the severity of AD (very mild to severe); no alterations of PlsEtns content and molecular species in cerebellar gray matter despite dramatic alterations in white matter. 10 mol% deficiencies was present in mice at age of 18 months in cerebral cortices but not in cerebellum. |
the production of Aβ from amyloid precursor proteins [63]. Thus decreased PlsEtns in AD may facilitate Aβ production. Furthermore, one in vitro study has shown that Aβ aggregation can be modulated by plasmalogens [64]. On the other hand, it has also been shown that increased Aβ and ROS reduced the expression of a rate-limiting enzyme, alkyl-dihydroxyacetone phosphate-synthase, for plasmalogens de novo synthesis, due to the dysfunction of peroxisomes where plasmalogens are biosynthesized, resulting in a decrease in plasmalogen level [60]. Finally, since PlsEtns are major endogenous lipid constituents that facilitate membrane fusion of synaptic vesicles associated with neurotransmitter release, loss of PlsEtns might be expected to adversely affect synaptic structure and function, thus potentially contributing to the synaptic dysfunction and neurotransmitter depletion observed in AD [1, 3, 59].

Decreased levels of plasmalogens have been observed in neuroinflammation, Aβ accumulation, ROS production, and plasmalogen deficiency [59]. Furthermore, degradation of PlsEtns by the enzyme, plasmalogen-selective phospholipase A2 (Pls-PLA2), releases DHA or arachidonic acid from the sn-2 position of the glycerol backbone, and this process is possibly activated by ceramide produced under inflammatory conditions which might contribute to the loss of PlsEtns in the brain [65, 66]. Arachidonic acid is a substrate for the synthesis of prostaglandins, thromboxanes and leukotrienes. Metabolites derived from DHA include resolvins, maresins, docosatetraenes and neuroprotectins [1, 67]. All of these molecules regulate inflammatory responses, with arachidonic acid and its derivatives involved in pro-inflammatory processes and DHA and its derivatives involving in anti-inflammatory processes [13, 55, 68] (Fig. 3).

An increasing number of studies have shown that PlsEtns deficiency is associated with AD pathology. These findings have led the researchers to propose a role of these molecules as a potential biomarker for AD. However, since decreased levels of circulating plasmalogens are also found in a number of other clinical
disorders, including ischemic cerebrovascular disease, hypertension, uremia, and hyperlipidemia, the utility of PlsEtns as a biomarker for AD needs to be further studied, as suggested by Wood [3, 50]. Taken together, future studies should focus on the determination of signature molecular species of PlsEtns associated with AD. This may provide specific evidence on the efficacy of PlsEtns as a reliable biomarker for AD.

**Plasmalogens as a potential therapy for AD**

Several researches have focused on the plasmalogens replacement therapy in animals, and reported promising outcomes. Katafuchi et al. [59] reported that intraperitoneal administration of purified plasmalogens for 7 days attenuated the neuroinflammation in the hippocampus of adult male C57/6j mice, which had been induced by lipopolysaccharide. Plasmalogen treatment also abolished Aβ protein accumulation in the hippocampus, and this was correlated with the suppressed reduction of the plasmalogen content in the hippocampus [59]. Feeding a test diet containing 10 wt% of phospholipids to rats for 7 days has been found to increase plasmalogen concentration by threefold in blood plasma and by 25% in the liver [21]. Supplementation with 0.1% PlsEtn for 4 weeks in
Zucker diabetic fatty (ZDF) rats and for 9 weeks in healthy Wistar rats reduced the plasma cholesterol and phospholipid concentrations; corresponding with this, an increase in erythrocyte PlsEtn and phosphatidylethanolamine was observed [17]. Oral administration of plasmalogens precursor PPI-1011 (100 mg/kg/day) to C57/6 J mice for 2 weeks restored the reduced levels of PlsEtns in plasma and brain, and this plasmalogen restoration was associated with a stimulated re-myelination of neuronal cells [57].

Little information is available on the therapeutic efficacy of plasmalogens in humans, suggesting a need for future research. A recent randomized, double-blind, placebo-controlled clinical study [15] reported a significant improvement in memory (as shown in Wechsler Memory Scale-Revised test) among female patients with mild AD aged below 77 years, after 24 weeks of oral administration with 1 mg/day of purified plasmalogens extracted from scallops. The study was conducted in multiple centres with a total of 276 patients (140 in the treatment group and 136 in the placebo group) aged 60 to 85 years. Correspondingly, the plasma PlsEtn in mild AD patients showed a significantly greater decrease in the placebo group compared with the treatment group.

The molecular mechanisms underlying the beneficial effects of PlsEtns on AD have been explored predominantly through in vitro studies. It was found that plasmalogens strongly reduce activity of γ-secretase, a membrane-associated aspartic protease that catalyzes the final step of Aβ synthesis, i.e. produce several Aβ peptides of different lengths such as Aβ40, Aβ42 and Aβ43 [32, 46]. Increased aggregation of Aβ42 and Aβ43 can result in the deposition of Aβ and is a common outcome of the familial AD [69]. Studies have also shown that PlsEtns prevented neuronal cell death by enhancing phosphorylation of protein kinase B (AKT) and extracellular signal-regulated kinase (ERK) signaling in neuronal cells, and this was through the activation of orphan GPCR (G-protein coupled receptor) proteins. Over-expression of GPCRs enhanced plasmalogen-mediated phosphorylation of ERK and AKT in neuronal cells, while GPCRs-mediated cellular signaling was reduced significantly when the endogenous PlsEtns levels were reduced [70, 71]. Furthermore, the inhibitory effect of PlsEtns on the death of primary mouse hippocampal neuronal cells was found to be associated with the inhibition of caspase-9 and caspase-3 cleavages, indicating the anti-apoptotic action of PlsEtns in the brain [71]. More in-depth animal studies are required to explore further the molecular mechanisms associated with the actions of PlsEtns in AD in order to gain a better understanding of these molecules and to evaluate their use as an effective therapeutic approach to correcting AD pathology and function.

Conclusion

Many studies have shown that there is a link between PlsEtns deficiency and AD, although it is not clear whether the decrease of PlsEtns in the patients with AD is the cause or the consequence of the disease. Reductions of PlsEtns levels have been reported in plasma, serum, cerebrospinal fluid and brain tissue of AD patients. This suggests PlsEtns might be a candidate as a potential AD biomarker. However, due to the fact that decreased levels of circulating PlsEtns are also found in a number of other clinical disorders, further in-depth investigations are required to determine the signature molecular species of PlsEtns associated with AD. Little is known about the clinical efficacy of plasmalogens on AD treatment, and more intervention studies with PlsEtns replacement therapy in AD patients are warranted given the promising outcomes in animal studies. Future in vivo studies of molecular mechanisms associated with actions of PlsEtns would also help to determine the potential use of PlsEtns as a new therapeutic agent for AD.

Abbreviations

AD: Alzheimer’s disease; ADHAP-S: Alkyl dihydroxyacetone phosphate synthase; AKT: Protein kinase B; Aβ: β-amyloid; DHA: Docosahexaenoic acid; DHAP: Dihydroxyacetone phosphate; DHAPAT: Dihydroxyacetone phosphate acyltransferase; ERK: Extracellular signal-regulated kinase; FARI/2: Acyl-CoA reductase 1 and 2; GPCR: G-protein coupled receptor; LDL: Low density lipoprotein; PET: Positron emission tomography; PlChos: Choline plasmalogens; PlsEtns: Ethanolamine plasmalogens; ROS: Reactive oxygen species; VLCFAs: Very long chain fatty acids

Acknowledgements

This work was supported by the special study program of Victoria University, Australia.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Authors’ contributions
XQS and AJS conceived the research; XQS drafted the manuscript; XQS, AJS and JW revised and approved the final version of manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Institute for Health and Sport, Victoria University, P.O. Box 14428, Melbourne, VIC 8001, Australia. 2Department of Pathology, University of Mississippi Medical Centre, Jackson, MS 39213, USA. 3Faculty of Health, Deakin University, Geelong, VIC 3217, Australia. 4Department of Nutrition, Dietetics and Food, Monash University, Notting Hill, VIC 3800, Australia.
Alzheimer's disease. Sci World J. 2012;2012. Article ID 141240. http://dx.doi.org/10.1100/2012/141240.

47. Molina J, Jimenez-Jimenez F, Vargas C, Gomez P, De Bustos F, Ortí-Paréja M, Tallon-Barranco A, Benito-León J, Arenas J, Enríquez-de-Salamanca R. Cerebrospinal fluid levels of non-neurotransmitter amino acids in patients with Alzheimer's disease. J Neural Transm. 1998;105:279–86.

48. Yamashita S, Kiko T, Fujisawa H, Hashimoto M, Nakagawa K, Kinoshita M, Furukawa K, Arai H, Miyazawa T. Alterations in the levels of amyloid-β, phospholipid hydroperoxide, and plasmalogen in the blood of patients with Alzheimer's disease: possible interactions between amyloid-β and these lipids. J Alzheimers Dis. 2016;50:527–37.

49. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, Heath LL. Towards a whole-body systems [multi-organ] lipidomic platform. J Lipid Res. 2007;48:2485–98.

50. Wood PL, Locke VA, Herling P, Passaro A, Vigna GB, Volpato S, Valacchi G,ARGV. Plasmalogen deficit: a logical causative factor in Alzheimer's disease and dementia. J Neuroinflammation. 2016;13:257.

51. Ren H, Luo C, Feng Y, Yao X, Shi Z, Liang F, Kang JX, Wan J-B, Pei Z, Su H. Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease. Curr Alzheimer Res. 2005;2:65–77.

52. Grimm MO, Metz J, Stahlmann CP, Haupenthal VJ, Blümel T, Stötzl H, Grimm HS, Hartmann T. Eicosapentaenoic acid and docosahexaenoic acid increase the degradation of amyloid-β by affecting insulin-degrading enzyme. Biochem Cell Biol. 2016;94:534–42.

53. Hopperton KE, Trépanier M-O, Giuliano V, Bazinet RP. BRAIN OMEGA-3 polyunsaturated fatty acids modulate microglia cell number and morphology in response to intracerebroventricular amyloid-β 1–40 in mice. J Neuroinflammation. 2016;13:257.

54. Ren H, Luo C, Feng Y, Yao X, Shi Z, Liang F, Kang JX, Wan J-B, Pei Z, Su H. Omega-3 polyunsaturated fatty acids promote amyloid-β clearance from the brain through mediating the function of the glymphatic system. FASEB J. 2017;31:282–93.

55. Astarita G, Piomelli D. Towards a whole-body systems [multi-organ] lipidomics in Alzheimer’s disease. Prostaglandins Leukot Essent Fatty Acids (PLEFA). 2011;85:197–203.

56. Crawford MA, Bazinet RP, Sinclair AJ. Fat intake and CNS functioning: ageing and disease. Ann Nutr Metab. 2009;55:202–28.

57. Wood PL, Khan MA, Markidy R, Smith T, Goodenowe DB. Plasmalogen deficits: a new and testable hypothesis for the etiology of Alzheimer's disease: In: In Alzheimer's Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets. InTech. 2011. https://doi.org/10.5772/17630.

58. Kou J, Kovacs GG, Vargas C, Gomez P, De Bustos F, Ortí-Paréja M, Tallon-Barranco A, Benito-León J, Enríquez-de-Salamanca R, Enríquez-de-Salamanca. Cerebrospinal fluid levels of non-neurotransmitter amino acids in patients with Alzheimer's disease. J Neural Transm. 1998;105:279–86.

59. Yanashita S, Kiko T, Fujisawa H, Hashimoto M, Nakagawa K, Kinoshita M, Furukawa K, Arai H, Miyazawa T. Alterations in the levels of amyloid-β, phospholipid hydroperoxide, and plasmalogen in the blood of patients with Alzheimer's disease: possible interactions between amyloid-β and these lipids. J Alzheimers Dis. 2016;50:527–37.

60. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, Heath LL. Towards a whole-body systems [multi-organ] lipidomics platform. J Lipid Res. 2007;48:2485–98.

61. Wood PL, Locke VA, Herling P, Passaro A, Vigna GB, Volpato S, Valacchi G, AVR. Plasmalogen deficit: a logical causative factor in Alzheimer's disease and dementia. J Neuroinflammation. 2016;13:257.

62. Reiss D, Beyer K, Engelmann B. Delayed oxidative degradation of polyunsaturated diacyl phospholipids in vitro. Biochem J. 1997;323:807–14.

63. Hartmann T, Kuchenbecker J, Grimm MO. Alzheimer's disease: the lipid connection. J Neurochem. 2007;103:159–70.

64. Lee J, Culyba EK, Powers ET, Kelly JW. Amyloid-β forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol. 2011;7:602–9.

65. Farooqui AA, Horrocks LA. Plasmalogens, phospholipase A2, and docosahexaenoic acid turnover in brain tissue. J Mol Neurosci. 2001;16:263–72.

66. Astarita G, Piomelli D. Towards a whole-body systems [multi-organ] lipidomics in Alzheimer’s disease. Prostaglandins Leukot Essent Fatty Acids (PLEFA). 2011;85:197–203.

67. Di Paolo G, Kim T-W. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci. 2011;12:284–96.

68. Florent-Bechard S, Desbene C, Garcia P, Allouche A, Youssef I, Escanye M-C, Koziel V, Hanse M, Malaplate-Armand C, Stenger C. The essential role of lipids in Alzheimer's disease. Biochimie. 2009;91:804–9.

69. Selkoe DJ. Resolving controversies on the path to Alzheimer’s therapeutics. Nat Med. 2011;17:1060–5.

70. Hossain MS, Mineno K, Katafuchi T. Neuronal orphan G-protein coupled receptor proteins mediate plasmalogens-induced activation of ERK and Akt signaling. PLoS One. 2016;11:e0150846.

71. Hossain MS, Ifuku M, Take S, Kawamura J, Mlake K, Katafuchi T. Plasmalogens rescue neuronal cell death through an activation of AKT and ERK survival signaling. PLoS One. 2013;8:e33508.